Healthcare Industry News: metabolic disease
News Release - May 31, 2012
Catabasis Pharmaceuticals Appoints Henry Rath to Vice President, Business DevelopmentCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Catabasis Pharmaceuticals, a clinical stage biopharmaceutical company dedicated to the discovery and development of innovative, effective and safe medicines for the treatment of inflammatory and metabolic diseases, today announced the appointment of Henry Rath to the position of vice president, business development. In this new role, Mr. Rath will lead the company’s corporate development strategy.
“Henry’s extensive transactional experience with global biotechnology and pharmaceutical companies makes him a strong addition to the management team,” said Jill C. Milne, Ph.D., chief executive officer and co-founder of Catabasis. “Henry’s leadership and breadth of experience across multiple therapeutic areas will be important as we accelerate our business development and partnering activities and identify value creation opportunities.”
Mr. Rath has more than 19 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Catabasis, he served as the executive director of corporate development at Amgen, where he was responsible for Amgen’s corporate development activities in oncology and metabolic disorders, as well as expanding Amgen’s commercial footprint internationally. Mr. Rath also began Amgen’s business development function based in Zug, Switzerland, in which he was responsible for scouting and overseeing local transactions. He has held positions in both consulting and banking firms with a focus on the biotechnology sector. Mr. Rath holds an M.B.A. from the Wharton School of the University of Pennsylvania and received his bachelor’s degree from Harvard College.
“I am pleased to join Catabasis to help advance the company’s corporate strategy as the company enters this next phase of growth,” said Mr. Rath. “Catabasis has developed a robust pipeline of new chemical entities that have the potential to treat a range of inflammatory and metabolic diseases. The company has been on an impressive growth trajectory and I look forward to working with the management team to continue to drive the company’s promising programs forward.”
Catabasis is a clinical stage company dedicated to the discovery and development of innovative, effective and safe medicines for the treatment of inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that produce mechanistic synergy on a targeted pathway. The company’s technology platform utilizes pathway pharmacology and has produced a robust pipeline of new chemical entities leveraging its proprietary linker technology. The company was founded in 2008 and is headquartered in Cambridge, Mass. Please visit http://www.catabasispharma.com for more information.
Source: Catabasis Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.